Migdal Insurance & Financial Holdings Ltd. C4 Therapeutics, Inc. Transaction History

Migdal Insurance & Financial Holdings Ltd.

$5.99 Billion
Q2 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 02, 2022	SELL	$19.99 - $33.23 $12,093 - $20,104	-605 Closed	0 $0
Q4 2021 Feb 02, 2022	SELL	$29.39 - $46.86 $17,310 - $27,600	-589 Reduced 49.33%	605 $20,000
Q3 2021 Nov 16, 2021	BUY	$35.91 - $50.5 $42,876 - $60,297	1,194 New	1,194 $53,000

Others Institutions Holding CCCC

# of Institutions

122

Shares Held

53.8M

Call Options Held

331K

Put Options Held

145K

Ra Capital Management, L.P. Boston, MA

4.88M
Shares

$29.3 Million
0.34% of portfolio
Wasatch Advisors Inc Salt Lake City, UT

4.85M
Shares

$29.1 Million
0.12% of portfolio
Black Rock Inc. New York, NY

4.55M
Shares

$27.3 Million
0.0% of portfolio
Soleus Capital Management, L.P. Greenwich, CT

4.05M
Shares

$24.3 Million
1.9% of portfolio
Vanguard Group Inc Valley Forge, PA

3.56M
Shares

$21.3 Million
0.0% of portfolio

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $293M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account